Country not found in response Financial Implications in Management of Multidrug Resistant Tuberculosis in India
International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 137 | Views: 342

Research Paper | Medicine Science | India | Volume 6 Issue 1, January 2017 | Popularity: 6.1 / 10


     

Financial Implications in Management of Multidrug Resistant Tuberculosis in India

Dr. Jairaj P Nair, Dr. Amita U Athavale, Dr. Vijay S Khatri, Dr. Tanjul Saxena


Abstract: Aim To calculate total cost incurred by patients for Multi-drug Resistant Tuberculosis (MDR-TB) management and evaluate their financial resources. Financial details regarding MDR-TB management were collected from 30 patients. Average daily drugs cost was Rs.166.83. Average family monthly income was Rs.8333.33. Average Per Capita Income was Rs.1473.67. Financial help for treatment was provided by self-funding, relatives, socio-religious groups, hospital supply & stockists. Total cost of MDR-TB management is Rs.140752.50. Including sensitive first line MDR-TB drugs reduces cost remarkably.90 % of the study group belonged to economically productive age group. Institutional treatment is the cheapest mode.


Keywords: Economical, Resources, funding, Cost, Expensive


Edition: Volume 6 Issue 1, January 2017


Pages: 535 - 539


DOI: https://www.doi.org/10.21275/ART20164116


Please Disable the Pop-Up Blocker of Web Browser

Verification Code will appear in 2 Seconds ... Wait



Text copied to Clipboard!
Dr. Jairaj P Nair, Dr. Amita U Athavale, Dr. Vijay S Khatri, Dr. Tanjul Saxena, "Financial Implications in Management of Multidrug Resistant Tuberculosis in India", International Journal of Science and Research (IJSR), Volume 6 Issue 1, January 2017, pp. 535-539, https://www.ijsr.net/getabstract.php?paperid=ART20164116, DOI: https://www.doi.org/10.21275/ART20164116

Top